Topics

Glioblastoma | Treatment | Clinical trials | Tumor treating fields

Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Tumor treating fields

Goldlust SA, Singer S, Cappello LA, AlMekkawi AK, Lee KD, Ingenito AC, Lewis BE, Nyirenda T, Azmi H, Kaptain GJ.
Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma.
Neurooncol Adv. 2024 Jul 29;6(1):vdae129. doi: 10.1093/noajnl/vdae129. PMID: 39211521. Interventional study.ˍ

Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman M, Tran DD.
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Med. 2025 Jun 3:100708. doi: 10.1016/j.medj.2025.100708. PMID: 40466642. Interventional study. ˍ

Mikic N, Lukacova S, Skjøth-Rasmussen J, Poulsen FR, Hauerberg J, Laursen RJ, Ettrup KS, Møller S, Haslund CA, Dahlrot RH, Cortnum SOS, Sindby AK, Von Oettingen G, Valentin JB, Solheim O, Solheim TS, Sørensen JCH, Wong ET, Korshøj AR.
Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial.
Neurooncol Adv. 2025 Nov 20;7(1):vdaf245. doi: 10.1093/noajnl/vdaf245. PMID: 41473750. Interventional study. ˍ